Thermo Fisher Prices $2.2B in Senior Notes | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has priced three series of senior notes totaling $2.2 billion in aggregate.

The firm is offering $300 million aggregate principal amount of 2.05 percent senior notes due 2014; $900 million aggregate principal amount of 3.2 percent senior notes due 2016; and $1 billion aggregate principal amount of 4.5 percent senior notes due 2021.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.